ArticleFrontiers in pharmacology2022

Structure-Based Design of 2-Aminopurine Derivatives as CDK2 Inhibitors for Triple-Negative Breast Cancer.

Hanzhi Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.